Literature DB >> 14691478

Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Denise Kelly1, Jamie I Campbell, Timothy P King, George Grant, Emmelie A Jansson, Alistair G P Coutts, Sven Pettersson, Shaun Conway.   

Abstract

The human gut microflora is important in regulating host inflammatory responses and in maintaining immune homeostasis. The cellular and molecular bases of these actions are unknown. Here we describe a unique anti-inflammatory mechanism, activated by nonpathogenic bacteria, that selectively antagonizes transcription factor NF-kappaB. Bacteroides thetaiotaomicron targets transcriptionally active NF-kappaB subunit RelA, enhancing its nuclear export through a mechanism independent of nuclear export receptor Crm-1. Peroxisome proliferator activated receptor-gamma (PPAR-gamma), in complex with nuclear RelA, also undergoes nucleocytoplasmic redistribution in response to B. thetaiotaomicron. A decrease in PPAR-gamma abolishes both the nuclear export of RelA and the anti-inflammatory activity of B. thetaiotaomicron. This PPAR-gamma-dependent anti-inflammatory mechanism defines new cellular targets for therapeutic drug design and interventions for the treatment of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691478     DOI: 10.1038/ni1018

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  304 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 2.  The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases.

Authors:  Helena Tlaskalová-Hogenová; Renata Stěpánková; Hana Kozáková; Tomáš Hudcovic; Luca Vannucci; Ludmila Tučková; Pavel Rossmann; Tomáš Hrnčíř; Miloslav Kverka; Zuzana Zákostelská; Klára Klimešová; Jaroslava Přibylová; Jiřina Bártová; Daniel Sanchez; Petra Fundová; Dana Borovská; Dagmar Srůtková; Zdeněk Zídek; Martin Schwarzer; Pavel Drastich; David P Funda
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 3.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

4.  Drosophila lifespan enhancement by exogenous bacteria.

Authors:  Ted Brummel; Alisa Ching; Laurent Seroude; Anne F Simon; Seymour Benzer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-20       Impact factor: 11.205

5.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 6.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

Review 7.  The immune system and the gut microbiota: friends or foes?

Authors:  Nadine Cerf-Bensussan; Valérie Gaboriau-Routhiau
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

8.  Effects of oral commensal and pathogenic bacteria on human dendritic cells.

Authors:  T Chino; D M Santer; D Giordano; C Chen; C Li; C-H Chen; R P Darveau; E A Clark
Journal:  Oral Microbiol Immunol       Date:  2009-04

Review 9.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

10.  PPARγ is an E3 ligase that induces the degradation of NFκB/p65.

Authors:  Yongzhong Hou; France Moreau; Kris Chadee
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.